Becker's Healthcare May 25, 2023
Paige Twenter

The FDA granted Pfizer’s popular COVID-19 antiviral treatment, Paxlovid, full approval on May 25.

Paxlovid (nirmatrelvir and ritonavir) was given emergency use authorization in December 2021, and that EUA was tweaked in February 2023 to allow providers to prescribe the drug to patients who do not test positive for COVID-19 but present symptoms.

Other COVID-19 treatments are approved, but Paxlovid is the first approved oral treatment for the coronavirus, according to Pfizer. The jump from emergency use authorization to approval means the FDA reviewed and found positive results from longer data from clinical study participants and the manufacturer’s plants.

The five-day regimen is approved for treating mild to moderate COVID-19 in adults who are at high risk for...

Today's Sponsors

Upfront Healthcare

Today's Sponsor


Topics: FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Public Health / COVID
COVID Boosters See More Vaccine Hesitancy Than Flu & RSV Shots
WHO recommends dropping component of many flu vaccines
Insurers argue that they're not to blame for snags in COVID-19 vaccine rollout
Older adults’ vaccine plans concern infectious disease experts
As COVID infections rise, nursing homes still waiting for vaccines

Share This Article